Cardiol Therapeutics Class Stock Today
| CRDL Stock | CAD 2.95 0.06 1.99% |
Performance10 of 100
| Odds Of DistressLess than 38
|
Cardiol Therapeutics is selling at 2.95 as of the 15th of May 2024; that is -1.99 percent decrease since the beginning of the trading day. The stock's open price was 3.01. Cardiol Therapeutics has about a 38 percent probability of financial distress in the next few years of operation but had a somewhat ok performance during the last 90 days. Equity ratings for Cardiol Therapeutics Class are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 15th of February 2024 and ending today, the 15th of May 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
Cardiol Therapeutics Inc., a biotechnology company, engages in the research and commercial development of proprietary drug formulations for the treatment of heart failure and cancer. The company was incorporated in 2017 and is headquartered in Oakville, Canada. The company has 68.27 M outstanding shares of which 244.47 K shares are currently shorted by private and institutional investors with about 2.52 days to cover all short positions. More on Cardiol Therapeutics Class
Moving together with Cardiol Stock
| 0.62 | FGAA-U | FG Acquisition Corp | PairCorr |
Moving against Cardiol Stock
| 0.68 | ATS | ATS P Earnings Call Tomorrow | PairCorr |
| 0.64 | BBUC | Brookfield Business Corp | PairCorr |
| 0.52 | GOOS | Canada Goose Holdings Earnings Call Tomorrow | PairCorr |
Cardiol Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Cardiol Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Cardiol Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO President | David MBA | ||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | ||||
Cardiol Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Cardiol Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cardiol Therapeutics' financial leverage. It provides some insight into what part of Cardiol Therapeutics' total assets is financed by creditors.
| |||||
Cardiol Therapeutics Class (CRDL) is traded on Toronto Exchange in Canada and employs 6 people. Cardiol Therapeutics is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 200.03 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cardiol Therapeutics's market, we take the total number of its shares issued and multiply it by Cardiol Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Cardiol Therapeutics operates under Pharmaceuticals sector and is part of Health Care industry. The entity has 68.27 M outstanding shares of which 244.47 K shares are currently shorted by private and institutional investors with about 2.52 days to cover all short positions.
Cardiol Therapeutics Class has accumulated about 59.47 M in cash with (31.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.48.
Check Cardiol Therapeutics Probability Of Bankruptcy
Ownership AllocationCardiol Therapeutics holds a total of 68.27 Million outstanding shares. Cardiol Therapeutics Class shows 4.42 percent of its outstanding shares held by insiders and 13.0 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Cardiol Ownership Details
Cardiol Stock Price Odds Analysis
Contingent on a normal probability distribution, the odds of Cardiol Therapeutics jumping above the current price in 90 days from now is about 5.76%. The Cardiol Therapeutics Class probability density function shows the probability of Cardiol Therapeutics stock to fall within a particular range of prices over 90 days. Assuming the 90 days trading horizon Cardiol Therapeutics has a beta of 0.8178 suggesting as returns on the market go up, Cardiol Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Cardiol Therapeutics Class will be expected to be much smaller as well. Moreover, cardiol Therapeutics Class has an alpha of 1.3336, implying that it can generate a 1.33 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Cardiol Therapeutics to move above the current price in 90 days from now is about 5.76 (This Cardiol Therapeutics Class probability density function shows the probability of Cardiol Stock to fall within a particular range of prices over 90 days) .
Cardiol Therapeutics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Cardiol Therapeutics market risk premium is the additional return an investor will receive from holding Cardiol Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Cardiol Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Cardiol Therapeutics' alpha and beta are two of the key measurements used to evaluate Cardiol Therapeutics' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 5.21 | |||
| Semi Deviation | 4.26 | |||
| Standard Deviation | 7.94 | |||
| Variance | 63.09 |
Cardiol Stock Against Markets
Picking the right benchmark for Cardiol Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Cardiol Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Cardiol Therapeutics is critical whether you are bullish or bearish towards Cardiol Therapeutics Class at a given time. Please also check how Cardiol Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Cardiol Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Economic Indicators Now
Economic IndicatorsTop statistical indicators that provide insights into how an economy is performing |
| All Next | Launch Module |
Cardiol Therapeutics Corporate Management
Elected by the shareholders, the Cardiol Therapeutics' board of directors comprises two types of representatives: Cardiol Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cardiol. The board's role is to monitor Cardiol Therapeutics' management team and ensure that shareholders' interests are well served. Cardiol Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cardiol Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andrew MD | Chief Development | Profile | |
| Trevor Burns | Investor Relations | Profile | |
| Bernard BSc | Chief Officer | Profile | |
| MBA MBA | CEO Pres | Profile | |
| CA CMA | Corp CFO | Profile |
How to buy Cardiol Stock?
Before investing in Cardiol Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Cardiol Therapeutics. To buy Cardiol Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Cardiol Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Cardiol Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Cardiol Therapeutics Class stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Cardiol Therapeutics Class stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Cardiol Therapeutics Class, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Cardiol Stock please use our How to Invest in Cardiol Therapeutics guide.
Already Invested in Cardiol Therapeutics Class?
The danger of trading Cardiol Therapeutics Class is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Cardiol Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Cardiol Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Cardiol Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Cardiol Therapeutics is a strong investment it is important to analyze Cardiol Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cardiol Therapeutics' future performance. For an informed investment choice regarding Cardiol Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Complementary Tools for Cardiol Stock analysis
When running Cardiol Therapeutics' price analysis, check to measure Cardiol Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardiol Therapeutics is operating at the current time. Most of Cardiol Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cardiol Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardiol Therapeutics' price. Additionally, you may evaluate how the addition of Cardiol Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |